Our approved brands remain a key driver of performance, while expanded international partnerships and steady advancement in our clinical development programs further strengthen our position. We are also evaluating select acquisition opportunities that align with our strategic objectives. As we look ahead, we remain committed...

Cumberland’s business strategy has been to acquire and commercialize a portfolio of branded pharmaceuticals that we can grow through our dedicated sales organization domestically and through our partners internationally. We’ve also built an internal development capability, which enables us to develop and register new medicines,...

We are pleased to report several significant milestones that reinforce our mission of working together to provide unique products that improve the quality of patient care. Our latest updates include important research findings, growing Medicaid coverage and expanded product access. In October, we announced new...